semaglutide cardiovascular risk in Cardiometabolic Diseases: SELECTing the Target Population Semaglutide reduces cardiovascular events in

That was no easy task

Al mismo tiempo, Gallup seala que la tasa de obesidad entre los estadounidenses descendi al 36.4% en 2026, desde un mximo histrico del 39.9% en 2022, el ao posterior a la aprobacin por primera vez del medicamento GLP-1 Wegovy por la Administracin de Alimentos y Medicamentos (FDA) para el tratamiento de la prdida de peso

Depleted mucosal PG content consequently results in decreased mucus and bicarbonate generation, reduces mucosal blood flow and inhibits cell proliferation, disrupting the integrity of gastric mucosa

Good, consistent sleep (both before & after a procedure) is one of the most powerful tools to ensure a more comfortable surgical recovery

doi: 10.2147/CCID.S68424